chrisvoncsefalvay/vaers-outcomes huggingface dataset:
COVID Vaccine Breakthrough Case  Pfizer Dose 1 4/22/21 (ER8731) Pfizer Dose 2 5/14/21 (EW0168) COVID Positive 12/12/21  12/19/21: Patient is a 61-year-old male with a past medical history significant for COPD, hypertension, hepatitis-C, type 2 diabetes, BPH, OSA, obesity, tobacco user. The patient presents to the ED today with complaints of worsening shortness of breath. The patient states he tested positive for COVID-19 on 12/12/2021 and his symptoms began on 12/10/2021. The patient's accompanying symptoms include fatigue, generalized weakness, body aches, and cough. The patient denies fever, chills, sputum production, chest pain, nausea, vomiting or diarrhea.  The patient states he has used 15 albuterol nebulizer treatments since midnight last night due to shortness of breath. He states his shortness of breath worsens with exertion and he experiences dizziness and lightheadedness with ambulation. The patient is not vaccinated against COVID-19. He is an every day smoker, states he smokes about 0.5-1 packs per day. He denies any alcohol use or illicit drug abuse.   Upon arrival to ED patient's temperature is 99.2°, heart rate 108, respirations 22, pulse ox 92% on room air, blood pressure 132/94.  Patient was placed on 3 L oxygen via nasal cannula to maintain O2 saturations greater than 90% as patient had episode of desaturation with ambulation.  CT angio reveals no pulmonary embolism, patchy airspace disease in bilateral lungs likely represent viral pneumonia.  Patient's laboratory findings are significant for glucose 101, proBNP 197, d-dimer 0.70.  500 mg IV azithromycin, 1 g IV Rocephin, 125 mg IV Solu-Medrol, and DuoNeb x1 in the ED.  12/23/21: -Patient is a 61 yo male who is unvaccinated against COVID  who was being managed for COVID pneumonia with hypoxia  -He was managed with Ceftriaxone , Azithromycin , Decadron and remdesivir  -His symptoms improved  -Home oxygen test done showed he requires 3L oxygen on exertion and none at rest  -He will be discharged with 1 day course of levaquin, 7 days of decadron and covid supportive treatments  -Patient will be discharged.
Right arm very achy at injection site almost immediately. Entire right arm sore by 18 hrs post-injection, especially "under" the shot (i.e. in armpit). By 28 hrs post-injection (10pm on 1/4/22) entire body ached as if I had the flu. Couldn't find comfortable position for sleeping (and I sleep like a rock). Woke up at least 3 times during the night (highly unusual for me) due to body aches and right armpit swelling/aching. By 36 hrs post-injection (when I finally looked at my armpit) it was very swollen compared to my left.  Feels almost as if the lymph nodes were swollen. At the time of this composition (40 hrs post-injection) all-over body aches gone, right arm still sore at injection site (but has lessened) and armpit still tender/swollen/sore.
This spontaneous report was received from a Registered Nurse reporting to a multiple unspecified patients of unknown age and gender. Medical history and concurrent conditions were not provided. On an unknown dates, the patients were vaccinated with improperly stored doses of (Oka/Merck) VARIVAX (dose and route were not reported). 5 lots: #M000760, the expiration date: 06-JAN-2018, time out of range: 2,760 hours, lot # L000455, the expiration date: 06-JAN-2017, time out range: 1,640 hours, lot #M019641, the expiration date: 20-APR-2018, time out of range: 720 hours or lot #M010482, the expiration date: 01-MAR-2018, time out of range: 888 hours or lot # M019643 the expiration date: 20-APR-2018, Time out of range: 576 hours. The temperature was 21 degree F. There was no previous temperature excursion. The call was no due to data logger and no adverse effect reported. Additional information has been requested.
pt vax in 1996 & in 1999 pt was dx w/chickenpox that consisted of more than 300 skin lesions over entire body
Patient has a swollen area the size of an egg on the (L) arm. It is red, swollen, and itching. Came home from school.
Pt has a rash allover. Pt received vaccine on 4/27/04. Rash present itself on May 1, 2004. Upon examination, the pt had vesicles in different stages. Pt was febrile also.
Mom called office on 4/28/12 s/p immunization with sl. rash/knot on leg; provided cool compress and stated rash went away. Called office & sent picture today (5/3/12) with actual hives at site; given BENADRYL to reduce redness & hives.
My right arm from the second shot continues to itch & I can still see the needle mark. After 2nd shot I notice that at times both upper arms feel weak in the area from the injection sites downwards. At times both arms still have a mildly stabbing achy pain deep in the muscle. After I've mowed my lawn with a push mower both arms feel weak, & I have to sometimes just sit down because I feel weak all over. I also still have itching at the right arm injection site. I don't know if these are typical this long after the shots. I guess since I actually had had covid my reactions to the vaccines were awful-fevers of 101° along with horrible body aches just like I had with covid.  Or maybe this is normal. But I didn't think the arm pain & weakness would continue. I only took the vaccine because I was afraid my retinal vein occlusion could have something to do with covid blood clot issues, but I am aware there isn't enough research at this stage. But I did not want to get it again or the delta variant. Maybe my case can help with research, as I never noticed strange visual "spots" until after I had covid--they would come & go, & then in June became permanent unfortunately.
This spontaneous report as received from a pharmacy student refers to an unspecified number of patients. On an unknown date, an unspecified number of patiens may have been administered (Merck) VARIVAX (lotnumber and route of administration was not reported) that was exposed to an unsupported temperature excursion (stored between 6F and 10F for an unspecified period of time and the average overall temperature may not have been at 5F or below). No adverse effect was reported. No further information was available. There was not relatedness reported for (Merck) VARIVAX. Additional information has been requested.
swollen lymph nodes, itching, rash on right arm below elbow, red rashes appearing in other areas of body from itching (buttocks, leg, foot), fatigue, pain at injection site --- still itchy (as of today 5/29), need to take asthma inhaler and breathing treatment daily since having shot, brain fog/light headedness
4/20/21: Got the shot on Tuesday 4/20/21 at 9.35 am. felt a little light headed and my right hand felt a little numb right after the shot. went away but rest of the day felt tired. 4/21/21: 11 am got a fever of 99.8. i usually run about 97.1 4/22/21 - ok in the morning. starting the afternoon felt very dizzy and fever came back. slept the rest of the day.  4/23/21 - still felt dizzy. rested all day 4/24/21: started feeling better. by 4/25/21 I felt fine.
Tinnitus in left ear at 4 of 10 scale Tinnitus in right ear, 3 out of 10 Constant and has not abated.  2nd dose on April 4 did not increase or decrease the ringing.
I was vaccinated with the second dose of Moderna vaccine on 03-15 around 3 PM PST, at approximately 11:30 am PST on 03-17 I began to have tightness in my chest and a burning sensation like my asthma is about to flare up. At approximately 1:00 pm 03-17 I took Albuterol via my rescue inhaler and my symptoms improved only slightly and as of writing at 1:37 pm PST 03-17 I still feel a burning sensation in my breathing passages mainly in my chest area, very similar to when my asthma is flaring up as I previously stated.
Pt received Td vaccine on Mon. 04/11-stated it was painful when she received it. Stated she  had the beginning of a mild cold also, called Tuesday and c/o sore arm, temp. 101, body aches, and swelling to the arm- called again on Wednesday c/o severe pain to Left arm, slightly swollen, c/o rashe on back of arm, left  arm locking and having muscle spasms in upper arm radiation to shoulder and some funny sensations in hand.
pt recvd Td 21AUG92 & the following day devel chills & fever & rt upper area was sore & tender; pt took ASA & still has pain under the rt arm; both hands looked swollen, bluish & shiny w/o pain; felt like skin 'stretched';
Exactly 2 weeks after the injection, I developed symptoms of Bell's Palsey, with the left side of my face (left eye, left side of mouth) paralyzed with slight drooping, and inability to close my eye, or eat, and drink with the left side of my mouth.
RESIDENT RECEIVED PFIZER VACCINES 1/12/21 & 2/2/21. RESIDENT CONTRACTED COVID-19 AFTER BEING FULLY VACCINATED ON 9/22/21. RESIDENT HOSPITALIZED 9/23/21- 9/27/21.
Fridge temp went out of range by 4 degrees overnight sunday due to storm, clinic closed on 1/17. Vaccines were administered to patients in the morning
No additional AE details available.; 10 total doses of VARIVAX (6 doses) and PROQUAD (4 doses) that have been stored outside of recommended range have been administered to patients; This spontaneous report was received from an office manager in charge of vaccine storage and refer to a patient of unknown age and gender. Concomitant medications included sterile diluent (manufacturer unknown). Pertinent medical history and drug reactions/allergies were not reported.  On 28-JUN-2022, the patient was vaccinated with improperly stored varicella virus vaccine live (oka/merck) (VARIVAX) subcutaneous injection (lot #U039722, expiration date: 15-DEC-2023), administered for prophylaxis (strength, dose, and route of administration were not provided) (product storage error).  It was reported that the suspect vaccine was exposed to a temperature of 6 degree Fahrenheit (F) up to 14 F for 0 hour 50 minutes 0 second; 14 F up to 46 F (15 F) for 0 hour 30 minutes 0 second. There were no previous temperature excursions. No additional adverse event (AE) details were available.  This is one of the several report received from the same reporter.; Sender's Comments:  US-009507513-2207USA000680: US-009507513-2207USA000470: US-009507513-2207USA000563: US-009507513-2207USA000544:
Started running a fever 7/18/04 with a high of 101 degrees F.  On 7/25 broke out in a rash, small red dots on trunk and arms.  Saw doctor on 7/26/04 and he felt it was a reaction to the MMR vaccine administered.  No treatment given.
Administrated / after a below freezing temperature excursion; This case was reported by a physician via call center representative and described the occurrence of incorrect product storage in a 17-year-old male patient who received HAV (Havrix) (batch number yl532, expiry date 9th September 2022) for prophylaxis.   On 21st July 2021, the patient received Havrix. On an unknown date, unknown after receiving Havrix, the patient experienced incorrect product storage. On an unknown date, the outcome of the incorrect product storage was unknown.  Additional details provided were as follows: Physician reported that, the patient was administrated with Havrix after a below freezing temperature excursion, which led to incorrect product storage. No adverse event was reported. Reporter consented to follow-up. This case is 1 of 28 case linked by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021164802:same reporter US-GLAXOSMITHKLINE-US2021164789: US-GLAXOSMITHKLINE-US2021164795:Same reporter. US-GLAXOSMITHKLINE-US2021164801: US-GLAXOSMITHKLINE-US2021164788:same reporter US-GLAXOSMITHKLINE-US2021164783:same reporter US-GLAXOSMITHKLINE-US2021164777:same reporter US-GLAXOSMITHKLINE-US2021164779: US-GLAXOSMITHKLINE-US2021164792:same reporter US-GLAXOSMITHKLINE-US2021164793:same reporter US-GLAXOSMITHKLINE-US2021164784: US-GLAXOSMITHKLINE-US2021164781:same reporter US-GLAXOSMITHKLINE-US2021164791:same reporter US-GLAXOSMITHKLINE-US2021164787:same reporter US-GLAXOSMITHKLINE-US2021164775:same reporter US-GLAXOSMITHKLINE-US2021164771:same reporter US-GLAXOSMITHKLINE-US2021164800: US-GLAXOSMITHKLINE-US2021164803:same reporter US-GLAXOSMITHKLINE-US2021164769:same reporter US-GLAXOSMITHKLINE-US2021164786:Same reporter. US-GLAXOSMITHKLINE-US2021164794:Same reporter. US-GLAXOSMITHKLINE-US2021164798:Same reporter. US-GLAXOSMITHKLINE-US2021164799:Same reporter. US-GLAXOSMITHKLINE-US2021164804:Same reporter. US-GLAXOSMITHKLINE-US2021164805:Same reporter. US-GLAXOSMITHKLINE-US2021164806:Same reporter. US-GLAXOSMITHKLINE-US2021164808:Same reporter.
FLU LIKE SYMPTOM; This spontaneous report received from a patient concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, and batch number: UNKNOWN expiry: UNKNOWN) .5 ml, administered on 05-MAR-2021 to Left Deltoid for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 06-MAR-2021, the subject experienced flu like symptom. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of flu like symptom was not reported. This report was non-serious.
Two minutes after receiving the vaccine the patient felt weak, dizzy and fainted. The patient went to the ER experiencing a fever of 102F, dizziness, tachycardia and right anterior chest pain. The patient was given IV fluids. The patient had diarrhea on 08/14/2001 in the A.M.
Possible allergic reaction reported @ 11:30 AM. Hive on bilateral arms, neck, chin. Advised Pt to seek medical attention and to not take flu vaccine next year. She stated that she is allergic to many things and was dignosed last week with allergy to Angmention.
I have a swollen lymph node under my arm where I got the booster shot. Is that a common reaction.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Regulatory Authority. The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 3 (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose: 01), for COVID-19 Immunization; Bnt162b2 (Dose: 02), for COVID-19 Immunization. The following information was reported: LYMPHADENOPATHY (non-serious), outcome "unknown", described as "I have a swollen lymph node under my arm where I got the booster shot. Is that a common reaction."  Follow-up attempts completed; information about lot/batch number cannot be obtained. No further information is expected.
Fever, Arm pain, Chills and a headache. All the symptoms got worse after the second shot.
tingling in tongue; burning sensation; feels tight and not comfortable for swallowing; This spontaneous case was reported by a consumer and describes the occurrence of PARAESTHESIA ORAL (tingling in tongue), BURNING SENSATION (burning sensation) and DYSPHAGIA (feels tight and not comfortable for swallowing) in a 30-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 015M20A) for COVID-19 vaccination.     No medical history reported.    On 05-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Feb-2021, the patient experienced PARAESTHESIA ORAL (tingling in tongue), BURNING SENSATION (burning sensation) and DYSPHAGIA (feels tight and not comfortable for swallowing). At the time of the report, PARAESTHESIA ORAL (tingling in tongue), BURNING SENSATION (burning sensation) and DYSPHAGIA (feels tight and not comfortable for swallowing) outcome was unknown.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   No relevant concomitant medications were reported.  No treatment information was provided.
Pt. reported redness and swelling experienced 24-48 hours after vaccination. She described it being like "an egg", and the swelling was over an area of about 6 inches in diameter around the site of injection. At 72 hours - post-vaccine, swelling subsided.
Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 28-JUN-2016 the patient was vaccinated with an improperly stored dose of GARDASIL 9 0.5ml (lot # L038917, expiration date 20-FEB-2018, route unspecified). This specified lot number vaccine was exposed to temperature excursion twice. The total cumulative excursion time of the first time was 40 hours with the lowest recorded temperature of 34 Fahrenheit degree. The total cumulative excursion time of the second time was 304 hours with the lowest recorded temperature of 33 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse effect was reported. This is one of several reports received from the same source. Additional information has been requested.
started with itching on day 7 after vaccine the inching got worse on Day 10 and a large sized hive formed on my arm just below the injection area with a strip that wrapped to the back of my arm in the evening of day 10 and became extremely itchy.
Relapsing Remitting Multiple Sclerosis; chills; severe headache; felt terrible; had no urinary control; fell; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): 4615551.  A 55-year-old female patient received BNT162b2 (BNT162B2), on 28Mar2021 as dose 1, single (Batch/Lot number: unknown) and on 07May2021 as dose 2, single (Batch/Lot number: unknown) at the age of 54 years for covid-19 immunisation. The patient's relevant medical history included: "Multiple Sclerosis" (ongoing); "ear infections" (unspecified if ongoing). Concomitant medication(s) included: OCREVUS; COPAXONE. Past drug history included: Morphine sulfate, reaction(s): "allergic to morphine sulfate". Vaccination history included: Tetanus shots (bad reaction to Tetanus shots), for Immunization, reaction(s): "bad reaction to Tetanus shots". The following information was reported: MULTIPLE SCLEROSIS RELAPSE (medically significant), outcome "unknown", described as "Relapsing Remitting Multiple Sclerosis"; CHILLS (non-serious), outcome "unknown"; HEADACHE (non-serious), outcome "unknown", described as "severe headache"; FEELING ABNORMAL (non-serious), outcome "unknown", described as "felt terrible"; URINARY INCONTINENCE (non-serious), outcome "unknown", described as "had no urinary control"; FALL (non-serious), outcome "unknown", described as "fell". On unknown date, it was reported that patient experienced: chills, severe headache, felt "terrible," had no urinary control and fell.  The information on the batch/lot number for [BNT162B2] has been requested and will be submitted if and when received.
Client reports uneventful night after receiving vaccine. Day two, client noted mild itching before bed. Day three when client awoke, he experienced rash, itching, and pain on the right side of his torso, back, neck, shoulder, and armpit. Day three the client saw his PCP who referred him to a dermatologist, the dermatologist in turn referred him to an immunologist who confirmed the shingles diagnosis. Diagnosis based on assessments of providers  - client denies any specific imaging or studies done outside of a bloodwork panel that he reports was all WNL. Client currently reports feeling "about 80% recovered" and still experiences what he described as internal pain, with the outward rash spots drying/scabbing and fall
i have them too, i  got them after my vaccine; This spontaneous case was reported by a consumer and describes the occurrence of VITREOUS FLOATERS (i have them too, i  got them after my vaccine) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 immunization.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VITREOUS FLOATERS (i have them too, i  got them after my vaccine). At the time of the report, VITREOUS FLOATERS (i have them too, i  got them after my vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Most recent FOLLOW-UP information incorporated above includes: On 11-Aug-2021: Follow-up received contains no new information.
NAUSEA; HEADACHE; MUSCLE PAIN; COUGH MUCUS; FEVER; This spontaneous report received from a consumer concerned a patient of unspecified age. The patient's height, and weight were not reported. The patient's past medical history included covid-19, and concurrent conditions included seasonal allergies, and other pre-existing medical conditions included the patient had a allergy of pain medicines. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: 1805018, expiry: UNKNOWN) dose was not reported, administered on 06-MAR-2021 to Left Arm for prophylactic vaccination. No concomitant medications were reported. On 06-MAR-2021, the subject experienced fever. Laboratory data included: Body temperature (NR: not provided) 100.3 F. On 07-MAR-2021, the subject experienced nausea. On 07-MAR-2021, the subject experienced headache. On 07-MAR-2021, the subject experienced muscle pain. On 07-MAR-2021, the subject experienced cough mucus. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from nausea, and cough mucus on 07-MAR-2021, and had not recovered from fever, headache, and muscle pain. This report was non-serious.
Patient has she has been feeling extremely unwell, had a terrible headache, and had trouble breathing when moving around.
Had oral typhoid vaccine first week August 2002, travelled to Ecuador, developed typhoid fever with fever, diarrhea, vomiting, hypotension and dehydration on 12/8/02. Blood test for typhoid (+), stool culture done 12/13/02 (+) salmonella typhi, treatment included 2l IV fluids at host home Amoxicillin 500 TID for 2 weeks and Cipro 500 BID for 5 days; repeat stool culture in January - no salmonella typhi.
hair loss; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 75 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 01Oct2021 (Lot number: FF2590) at the age of 75 years as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (First vaccine, NDC/expiration: unknown, Lot: EC3182, Site: left arm), administration date: 01Sep2021, when the patient was 74 years old, for COVID-19 immunization. The following information was reported: ALOPECIA (non-serious) with onset 2021, outcome "not recovered", described as "hair loss".  Additional information: Vaccination facility type was pharmacy. Vaccine was not administered at a facility. No additional vaccines were administered on same date of the Pfizer suspect. No other vaccines were received within four weeks prior to the administration of bnt162b2. Patient reported losing her hair, the hair was falling out the size of a baseball after second vaccine. AE did not require visit to emergency or physician office. No investigation assessment was reported.   Follow-up attempts are completed. No further information is expected.